Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 29, 2025 09:07 ET | Source: Predictive Oncology Inc.

Predictive Oncology Inc. Announces Private Placements of $344 Million to Initiate a Digital Asset Treasury Strategy Focused on Aethir (ATH) Tokens

Shawn Matthews, CEO of DNA Holdings and Former CEO of Cantor Fitzgerald, will join the Board of Directors upon the closing of the private placements Predictive Oncology continues to execute on its...
September 25, 2025 08:00 ET | Source: Predictive Oncology Inc.

Predictive Oncology Announces 1-for-15 Reverse Stock Split

PITTSBURGH, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI), a leader in AI-driven drug development and discovery, today announced that it will effect a 1-for-15 reverse...
September 04, 2025 09:00 ET | Source: Predictive Oncology Inc.

Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer Patients

PITTSBURGH, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug development and discovery, and Every Cure, a leading nonprofit dedicated to...
August 14, 2025 07:00 ET | Source: Predictive Oncology Inc.

Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
July 15, 2025 09:00 ET | Source: Predictive Oncology Inc.

Predictive Oncology Issues Shareholder Letter: Well Financed to Support Expanded U.S. Availability and E.U. Launch of ChemoFx® and Pursuit of Other High-Value AI-Driven Drug Discovery and Development Opportunities

$10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiatives Discussions underway to expand adoption of ChemoFx...
July 08, 2025 09:00 ET | Source: Predictive Oncology Inc.

Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing

PITTSBURGH, July 08, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has entered into a standby equity purchase...
June 12, 2025 08:30 ET | Source: Predictive Oncology Inc.

Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp

PITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models...
May 27, 2025 08:35 ET | Source: Predictive Oncology Inc.

Court Denies Renovaro Motion for an Expedited Trial in July

PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro,...
May 22, 2025 08:15 ET | Source: Predictive Oncology Inc.

AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition

PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response...
May 20, 2025 08:30 ET | Source: Predictive Oncology Inc.

Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health"

Latest developments expand Predictive’s AI-driven drug discovery platform to include biomarker discovery and drug repurposing With the global biomarker discovery market valued at $14.5 billion in...